HDAC6 and neoplasm: Notably, an in vivo study employing animal models demonstrated that combining HDAC6 inhibition via ACY1215 with ICIs constitutes a potential therapeutic approach for ARID1A-mutated OCCC, effectively limiting tumor progression through a cytotoxic T-cell-dependent mechanism (139).